Literature DB >> 17851515

At what price?

Patricia M Danzon1.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17851515     DOI： 10.1038/449176a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

1.  Orphan drugs for rare diseases: is it time to revisit their special market access status?

Authors:  Steven Simoens; David Cassiman; Marc Dooms; Eline Picavet
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

2.  Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C.

Authors:  Medo Gutić; Miloš N Milosavljević; Slobodan M Janković
Journal:  Int J Clin Pharm       Date:  2022-10-15

3.  Cost-effectiveness of inguinal hernia surgery in northwestern Ecuador.

Authors:  Samuel D Shillcutt; David L Sanders; M Teresa Butrón-Vila; Andrew N Kingsnorth
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

Review 4.  Unintended effects of orphan product designation for rare neurological diseases.

Authors:  Sinéad M Murphy; Araya Puwanant; Robert C Griggs
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

5.  Patient Benefit of Clinical Research in Diversely Advanced African Developing Countries.

Authors:  Vanessa Strüver; Sheraz Ali; Firas Fneish; Gerhard Fortwengel
Journal:  Curr Ther Res Clin Exp       Date:  2021-11-24

6.  R&D incentives for neglected diseases.

Authors:  Nicola Dimitri
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.